The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Takeda Suspends Shipment of All ASKA Pharma Products
March 28, 2011
- Astellas Settles Dispute over Tarceva Patents with Teva
March 28, 2011
- JAMS Cancels 2011 General Assembly
March 28, 2011
- Fuso's Replacement Fluid in Short Supply
March 28, 2011
- Sales by Member Companies Up 0.2% in 2010: JCROA
March 28, 2011
- Most Scientific Meetings Postponed or Cancelled
March 28, 2011
- Maintain Electric Power to Ensure Stable Drug Supply: FPMAJ
March 28, 2011
- Drugstore Sales Up 3.5% in FY2010: JACDS
March 28, 2011
- Change in Prescription Form Proposed by JSGM President
March 28, 2011
- Requests for Frequent Delivery Abating in Tohoku: Wholesalers
March 28, 2011
- R&I to Downgrade Terumo Following Announcement of Acquisition of CaridianBCT
March 21, 2011
- Korosho to Extend HPV Vaccination Period for Girls Currently in 1st Grade of Senior High School
March 21, 2011
- JACDS May Violate Antimonopoly Act by Calling on Members Not to Offer Point Cards
March 21, 2011
- MSD K.K. Submits NDA for Caspofungin
March 21, 2011
- Nichiyakubo to Call For Improvement of Drug Substance Import System
March 21, 2011
- Eli Lilly's Gemzar Receives Add'l Indication for Ovarian Cancer
March 21, 2011
- Astellas to Challenge New Field of Regenerative Medicine
March 21, 2011
- Herceptin Approved for Gastric Cancer as Add'l Indication
March 21, 2011
- Shionogi Terminates Development of S-2367 for Obesity Drug in the US, Europe
March 21, 2011
- Stiripentol Designated as Orphan Drug
March 21, 2011
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…